Efficacy and Safety of Pseudomonas Aeruginosa for Intermediate and High-risk Non-muscle Invasive Bladder Cancer

Inclusion criteria:

1. Age ≥18 years old, both male and female;
2. Diagnosed as Intermediate or high risk non-muscle invasive bladder cancer, withprevious recurrent pathological diagnosis report and cystoscopy available.Intermediate risk was defined as the presence of one or two of the following: multipletumors, single tumor larger than 3cm, and/or recurrence (≥1 event in low-risk NMIBCwithin 1 year after diagnosis). High risk was defined as meeting any one of thefollowing: T1 tumor, G3 tumor, carcinoma in situ (CIS), multiple, recurrent and large (> 3cm) TaG1G2/ low-risk tumor (simultaneous);
3. Not receiving BCG or other immune drug infusion chemotherapy at the same time
4. Informed consent and signed informed consent form by patients and their families;
5. Clear consciousness and able to answer questions independently, Patients were asked tocomplete the questionnaire by themselves;
6. No history of neurological diseases, severe hematological diseases, and dysfunction ofheart, lung, liver, or kidney were observed.

Exclusion criteria:

1. Patients with other genitourinary system tumors or other organ tumors;
2. Patients with muscle invasive bladder urothelial carcinoma (≥T2);
3. Patients receiving chemotherapy, radiotherapy or immunotherapy within the past 4 weeks (excluding immediate postoperative intravesical chemotherapy);
4. Pregnant or lactating women, women of childbearing age who did not use effectivecontraception, and those who planned to become pregnant during the trial (includingthe partner of male subjects);
5. Known or suspected intraoperative bladder perforation;
6. Gross hematuria was present before enrollment, and the surgical wound was suspected tobe unhealed or damaged urinary mucosa;
7. Patients with cystitis, or previous treatment with other intravesical agents, whosebladder irritation significantly affected the evaluation of the study;
8. Patients who had participated in a clinical trial with other drugs within 3 monthsbefore enrollment;
9. Patients with known opioid or alcohol dependence;
10. Patients with any condition considered by the investigators to increase the risk ofthe subject or interfere with the conduct of the trial;